Studying the correlation between the loss of the expression of RASSF1A and the mutation state of RAC1 could expose a new avenue for the restoration of sensitivity to targeted therapy in B-RAF-driven melanomas as an alternative to RAC1 inhibitors since they have not been reported to be therapeutically beneficial. The gene discussed is BRAF; the disease is melanoma.